Table 2.
Vaccine candidates tested against Clonorchis sinensis in the rat model of infection (Modified from [53]).
| Vaccine Type | Protein | Worm Reduction Rate | Egg Reduction Rate |
|---|---|---|---|
| DNA (pcDNA3.1) | Cysteine proteinase | 31.5% | 15.7% |
| DNA (pcDNA3.1) | Fatty-acid-binding protein | 40.9% | 27.5% |
| Bacillus subtilis spore-based | Tegumental protein 22.3 kDa | 44.7% | 30.4% |
| Protein | Rho GTPase | 60.5% | 68.8% |
| Protein | 14-3-3 epsilon | 45.4% | 37.9% |
| Protein | Paramyosin | 54.3% | 50.9% |
| DNA (pcDNA3.1) | Paramyosin | 36.1% | 38.8% |
| Protein | Enolase | 56.3% | ND |
| Protein | Enolase | 15.4% | ND |
| DNA (pcDNA3.1) | Enolase | 37.4% | ND |
| Bacillus subtilis spore-based | Enolase | 61.1% | 80.7% |
| Protein | Cathepsin B cysteine protease (CB2) | 41.0% | 33.6% |
| Protein | Cathepsin B cysteine protease (CB3) | 67.2% | 57.7% |
ND, not determined. For further details of each vaccine candidate trialled, see Reference [53].